AC
VIR icon

AXQ Capital’s Vir Biotechnology VIR Stock Holding History

AXQ Capital’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-23,820
Closed -$120K – 843
2025
Q2 		$120K Buy
23,820
+10,521
+79% +$56.4K 0.04% 504
2025
Q1 		$86.2K Buy
+13,299
New +$118K 0.03% 448
2023
Q2 		– Sell
-23,853
Closed -$555K – 580
2023
Q1 		$555K Buy
+23,853
New +$610K 0.22% 150

Other funds holding VIR

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AXQ Capital's VIR Position: Q3 2025 in Review

AXQ Capital sold out of Vir Biotechnology (VIR) in Q3 2025, closing a stake of 23,820 shares — an estimated $120K sold.

AXQ Capital first reported a position in VIR in Q1 2023 and held it in 3 quarters. The position peaked at $555K in Q1 2023. 213 funds tracked by Wall St. Rank hold VIR as of Q3 2025.

  • AXQ Capital reported no remaining Vir Biotechnology position as of Q3 2025 after selling out during the quarter.
  • AXQ Capital sold 23,820 Vir Biotechnology shares in Q3 2025, an estimated $120K.
  • AXQ Capital first reported a position in Vir Biotechnology in Q1 2023 and held it in 3 quarters.
  • AXQ Capital's Vir Biotechnology position peaked at $555K in Q1 2023.
  • 213 funds tracked by Wall St. Rank held Vir Biotechnology as of Q3 2025.

Based on AXQ Capital's 13F filing for Q3 2025, filed 10 Nov 2025.